drugset / Trial / NCT00347165
Intravitreal Bevacizumab for Age-Related Macular Degeneration
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
Timeline
- Start
- 2005-09
- Primary completion
- 2006-06
- Completion
- 2006-09
Outcome
Outcome not reported
Stopped: “undefined”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg | Intravitreal |